Background: Calcium-channel blockers (CCBs) are highly effective in suppressing coronary spasm and are widely used as the standard therapy for coronary spastic angina, but it is unclear if CCB treatment completely suppresses the symptoms.
t is known that coronary spasm plays an important role in the pathogenesis of not only variant angina but also other ischemic heart diseases, such as resting angina, effort angina or acute myocardial infarction, which sometimes lead to sudden death. 1, 2 Calcium-channel blockers (CCBs) are highly effective in suppressing coronary spasm and are widely used as the standard therapy for coronary spastic angina (CSA). 1, 3, 4 The prognosis for coronary spasm is relatively good with CCBs, 5, 6 but lethal arrhythmias and/or sudden death can occur in patients without any medication. One could speculate that a substantial number of patients with coronary spasm are resistant to CCBs to some extent, and would have various persistent symptoms, which are usually mitigated by the medical treatment. Thus, more precise study is required to focus on those persistent clinical symptoms despite treatment for CSA. In this study, we examined the clinical course of the symptoms of coronary spasm in patients under treatment with CCBs.
Methods

Characteristics of the Study Patients
Between 1997 and 2005, 202 patients with CSA were evaluated by intracoronary injection of acetylcholine (ACh) during cardiac catheterization at the Jikei University School of Medicine. Among patients who fulfilled the diagnostic criteria of coronary spasm, those who had organic stenosis (>50%) were excluded. Other exclusion criteria were myocardial infarction within the past 30 days, acute coronary syndrome, heart failure, liver disease, creatinine level >1.5 mg/dl, apparent acute inflammation, and malignant diseases. With these selection criteria, 90 patients were enrolled (77 men, 13 women; mean age 59±9.3 years) and each gave informed consent.
Method of Inducing Coronary Spasm
Coronary spasm was induced by intracoronary injection of ACh after diagnostic catheterization in the morning, as previously reported. 7 In brief, nitrates, CCBs, β-adrenergic blockers, angiotensin-converting enzyme inhibitors (ACEI), angiotensin-receptor blockers (ARB), and other vasodilators or vasoconstrictors were withheld for >48 h. If the patient experienced chest pain, nitroglycerine was administered sublingually. During catheterization, ACh was injected in incremental doses of 20 and 50 μg into the right coronary artery and then 20, 50 and 100 μg into the left coronary artery under continuous monitoring of electrocardiogram (ECG) and blood pressure. Coronary spasm induced by this method usually disappeared spontaneously within 1-2 min and the left and right coronary artery could be examined separately unless severe spasm occurred necessitating prompt intra-arterial injection of isosorbide dinitrate (ISDN). At the end of the test, ISDN (0.1 mg) was injected into the coronary artery and angiography was again performed. Coronary spasm was defined as a total or subtotal occlusion or severe diffuse constriction of an epicardial coronary artery associated with transient myocardial ischemia as evidenced by ischemic ST changes on ECG.
Medical Treatment of Coronary Spasm
After the diagnosis of coronary spasm, conventional therapy was started with CCBs: diltiazem 100-200 mg/day or nifedipine 20-40 mg/day. When angina was refractory or adverse effects were developed, other CCBs or agents, such as nitrates [including ISDN, isosorbide mononitrate and nitroglycerin] or nicorandil, were prescribed.
Statistical Analysis
Cumulative incidence of repeat anginal attacks was estimated according to Kaplan-Meier method. The relationship between repeat attacks and patient background, angiographic characteristics or prescription at diagnosis was analyzed with the Cox proportional hazard test. Statistical significance was indicated by P<0.05.
Results
By intracoronary injection of ACh, we diagnosed definite coronary spasm in 90 patients without organic stenosis; 45 patients (50%) had multi-vessel spasm in the left and right coronary arteries. The coronary risk factors of these patients are summarized in Table 1 . Note there were 55 cigarette smokers (61.1%). Table 2 is a summary of the follow-up data: 10 patients were missed because they went directly from outpatients to their general practitioner and could not be followed in the hospital. Therefore, 80 patients were evaluated. The mean follow-up period was 1,796±1,169 days. Among the 80 patients, there were no cardiac deaths and 3 patients were admitted to hospital, 1 because of onset of non-Q wave myocardial infarction and 2 because of repeat anginal attacks. Both patients had voluntarily discontinued medical therapy. In our follow-up analysis, we found that 46 patients had symptoms of repeat angina. The Kaplan-Meier curve of the incidence of repeat anginal attacks within 8 years is shown in Figure 1 . The major symptoms were chest pain, chest oppression, zonesthesia, back pain, sore throat, thirst sensation, and cold sweats with chest pain. Most of the symptoms were similar to those manifesting before the treatment and frequently occurred in the early morning; although sometimes they occurred even during the day or several hours after drinking. Moreover, the attacks tended to especially appear under mental or physical stress. In 15 cases, the appearance of an organic lesion was checked during the follow up period using CAG, MSCT or stress RI, but was not detected in all cases.
CCBs were started in 88 of the 90 (97.8%) patients with CSA at diagnosis, but during the study period, we needed to change some of the medical therapy for the following reasons: side-effects of CCBs, refractory chest pain because of coronary spasm, and poor control of blood pressure. In 3 patients, CCBs were discontinued because of side-effects (eruption in 2, gingival overgrowth in 1), treatment was resumed in 1 patient with a different CCB and another 2 patients began CCBs therapy. Thus, the final number of patients under CCBs was 88/90 patients (97.8%), 55/90 patients (61.1%) were taking nitrates and 17/90 patients (18.9%) were taking nicorandil (Figure 2A) . The mean dose of nitrates or nicorandil is presented in Table 3 . Figure 2B shows the types of CCBs prescribed at diagnosis; of them, 5 patients had concomitant administration of 2 types. Table 4 shows the pattern of CCB administration. Forty-six patients were resistant to anginal attacks despite treatment with CCBs or other drugs in combination with the original CCBs.
The relationship between repeat attacks and patient background or angiographic characteristics is shown in Table 5 , and that between repeat attacks and prescription at diagnosis in Table 6 . Repeat attacks frequently occurred in patients taking nitrates (P<0.05).
Discussion
Coronary spasm occurs most often in the early morning and is sometimes silent. It is usually not induced by exercise during the day. Moreover, there are daily, weekly and monthly variations in the frequency of coronary spasm 8, 9 and the episodes of coronary spasm may not be detected even with ambulatory ECG monitoring. CCBs have been established as a standard treatment for CSA, 3, 4 but disease activity generally changes and resistance to therapy sometimes appears. One could speculate that the most cases of coronary spasm would not be completely controlled even with CCBs and thus a substantial number of patients with coronary spasm would be troubled by ongoing symptoms including resting chest pain early in the morning.
In the present study, we showed that the incidence of symptoms caused by repeat anginal attacks was 37.0% (27/73) within the first year, even after treatment with CCBs, and gradually increased year by year. Thus, it is clarified that a substantial number of repeat attacks occur even under treatment with CCBs. There might be a substantial number of potential patients when taking silent repeat attacks into consideration, as well the symptomatic attacks. 9 Thus, it is fair to say that CCBs do not completely suppress coronary spasm, although they are considered effective for the preventing spasm. 5, 6 In our analysis, nitrates were related to repeat attacks. When the physician thought the spasm was severe, he/she tended to prescribe nitrates in addition to CCBs. Other unclassified or unknown factors might have confounded the results. It is possible that nitrates induced a tolerance that makes the patient more susceptible to CSA.
The pathophysiology of coronary spasm is still unclear, but we have shown that endothelial nitric oxide (NO) activity is reduced and endothelial function impaired in the coronary arteries involved in spasm. 7 Also, it has been demonstrated that cigarette smoking increases oxidative stress, 10 which is a strong risk factor of coronary spasm. Furthermore, the patient's genetic background, namely endothelial NO synthase (eNOS) gene mutations, is strongly associated with the onset of coronary spasm. 11, 12 Recently, it was reported that coronary spasm is associated with chronic low-grade inflammation, 13 so measurement of high-sensitivity C-reactive protein levels may predict repeat attacks Abbreviation see in Table 3 . Table 3 .
in patients with coronary spasm. CCBs are effective vasodilators by blocking the entry of Ca 2+ into smooth muscle cells; however, it is still unclear whether CCBs have an antioxidant effect. In terms of reducing oxidative stress, ACEI, ARB or HMG-Co reductase inhibitors (statins) would be potential treatments for suppressing coronary spasm. There is increasing evidence that statins improve endothelial dysfunction and reduce cardiovascular events in patients with coronary artery disease, 14, [15] [16] [17] and it was recently shown that fluvastatin suppresses coronary spasm. 18 We thus need to evaluate repeat attacks under fluvastatin treatment in a large study population.
We examined the relationship between the patient's background and repeat attacks, but there was no clear relationship, including smoking at diagnosis. It is clear that smoking is a strong risk factor for coronary spasm 10 and we strongly recommend the patients to stop smoking; however, it was not clear whether they actually stopped smoking. Some of the patients might have continued or resumed smoking during the treatment. Also, it has been recently clarified that T -786 → C polymorphism of the eNOS gene is a strong risk factor for repeat attacks, 6 but we did not check the gene polymorphism, although genetic background might be related to the result showing no clear relationship between the patient's background and re-attacks ( Table 5 ).
In conclusion, CCBs are strongly recommended to improve the prognosis of coronary spasm, but they are unable to completely suppress the symptoms in many cases. To control symptoms and improve the quality of life, we may need to prescribe multiple CCBs or combine other drugs with CCBs. Further studies are required.
